HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Extended lymphadenectomy in elderly and/or highly co-morbid gastric cancer patients: A retrospective multicenter study.

AbstractBACKGROUND:
Gastrectomy with extended lymphadenectomy is considered the gold standard treatment for advanced gastric cancer, with no age- or comorbidity-related limitations. We evaluated the safety and efficacy of curative gastrectomy with extended nodal dissection, verifying survival in elderly and highly co-morbid patients.
METHODS:
In a retrospective multicenter study, we examined 1322 non-metastatic gastric-cancer patients that underwent curative gastrectomy with D2 versus D1 lymphadenectomy from January 2000 to December 2009. Postoperative complications, overall survival (OS), and disease-specific survival (DSS) according to age and the Charlson Comorbidity Score were analyzed in relation to the extent of lymphadenectomy.
RESULTS:
Postoperative morbidity was 30.4%. Complications were more frequent in highly co-morbid elderly patients, and, although general morbidity rates after D2 and D1 lymphadenectomy were similar (29.9% and 33.2%, respectively), they increased following D2 in highly co-morbid elderly patients (39.6%). D2-lymphadenectomy significantly improved 5-year OS and DSS (48.0% vs. 37.6% in D1, p < 0.001 and 72.6% vs. 58.1% in D1, p < 0.001, respectively) in all patients. In elderly patients, this benefit was present only in 5-year DSS. D2 nodal dissection induced better 5-year OS and DSS rates in elderly patients with positive nodes (29.7% vs. 21.2% in D1, p = 0.008 and 47.5% vs. 30.6% in D1, p = 0.001, respectively), although it was present only in DSS when highly co-morbid elderly patients were considered.
CONCLUSION:
Extended lymphadenectomy confirmed better survival rates in gastric cancer patients. Due to high postoperative complication rate and no significant improvement of the OS, D1 lymphadenectomy should be considered in elderly and/or highly co-morbid gastric cancer patients.
AuthorsS Rausei, L Ruspi, F Rosa, P Morgagni, D Marrelli, A Cossu, F C M Cananzi, R Lomonaco, A Coniglio, A Biondi, C Cipollari, L Graziosi, U Fumagalli, F Casella, P Bertoli, A di Leo, S Alfieri, G Vittimberga, F Roviello, E Orsenigo, V Quagliuolo, S Montemurro, G Baiocchi, R Persiani, M Bencivenga, A Donini, R Rosati, A Sansonetti, L Ansaloni, A Zanoni, F Galli, G Dionigi, Italian Research Group for Gastric Cancer (IRGGC)
JournalEuropean journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology (Eur J Surg Oncol) Vol. 42 Issue 12 Pg. 1881-1889 (Dec 2016) ISSN: 1532-2157 [Electronic] England
PMID27266816 (Publication Type: Journal Article, Multicenter Study)
CopyrightCopyright © 2016 Elsevier Ltd. All rights reserved.
Topics
  • Adenocarcinoma (epidemiology, surgery)
  • Adult
  • Age Factors
  • Aged
  • Aged, 80 and over
  • Cardiovascular Diseases (epidemiology)
  • Comorbidity
  • Dementia (epidemiology)
  • Diabetes Mellitus (epidemiology)
  • Disease-Free Survival
  • Female
  • Gastrectomy (methods)
  • Humans
  • Liver Diseases (epidemiology)
  • Lymph Node Excision (methods)
  • Male
  • Middle Aged
  • Postoperative Complications (epidemiology)
  • Pulmonary Disease, Chronic Obstructive (epidemiology)
  • Retrospective Studies
  • Stomach Neoplasms (epidemiology, surgery)
  • Survival Rate

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: